General MedicationsORALGeneric

REYATAZ

ATAZANAVIR SULFATE

Standard Dose

EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview REYATAZ is listed in Drugs@FDA under application 021567 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ATAZANAVIR SULFATE Form and strength CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2024-12-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview REYATAZ is listed in Drugs@FDA under application 021567 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ATAZANAVIR SULFATE Form and strength CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2024-12-05 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.